AU2017385958B2 - Tianeptine oxalate salts and polymorphs - Google Patents

Tianeptine oxalate salts and polymorphs Download PDF

Info

Publication number
AU2017385958B2
AU2017385958B2 AU2017385958A AU2017385958A AU2017385958B2 AU 2017385958 B2 AU2017385958 B2 AU 2017385958B2 AU 2017385958 A AU2017385958 A AU 2017385958A AU 2017385958 A AU2017385958 A AU 2017385958A AU 2017385958 B2 AU2017385958 B2 AU 2017385958B2
Authority
AU
Australia
Prior art keywords
tianeptine
oxalate
degrees
mono
hemi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017385958A
Other languages
English (en)
Other versions
AU2017385958A1 (en
Inventor
Michel CHIARUCCI
Mark T. Edgar
Serena Fabbroni
Stefano Luca Giaffreda
Enrico MODENA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharma Holdings Ltd
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Publication of AU2017385958A1 publication Critical patent/AU2017385958A1/en
Application granted granted Critical
Publication of AU2017385958B2 publication Critical patent/AU2017385958B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AU2017385958A 2016-12-28 2017-12-28 Tianeptine oxalate salts and polymorphs Ceased AU2017385958B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662439533P 2016-12-28 2016-12-28
US62/439,533 2016-12-28
PCT/IB2017/001709 WO2018122606A1 (en) 2016-12-28 2017-12-28 Tianeptine oxalate salts and polymorphs

Publications (2)

Publication Number Publication Date
AU2017385958A1 AU2017385958A1 (en) 2019-07-11
AU2017385958B2 true AU2017385958B2 (en) 2021-12-02

Family

ID=61283255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017385958A Ceased AU2017385958B2 (en) 2016-12-28 2017-12-28 Tianeptine oxalate salts and polymorphs

Country Status (13)

Country Link
US (2) US10449203B2 (cg-RX-API-DMAC7.html)
EP (1) EP3562812A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020503330A (cg-RX-API-DMAC7.html)
CN (1) CN110418785A (cg-RX-API-DMAC7.html)
AU (1) AU2017385958B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019013244A2 (cg-RX-API-DMAC7.html)
CA (1) CA3048324A1 (cg-RX-API-DMAC7.html)
IL (1) IL267708A (cg-RX-API-DMAC7.html)
MX (1) MX2019007891A (cg-RX-API-DMAC7.html)
MY (1) MY199385A (cg-RX-API-DMAC7.html)
NZ (1) NZ754797A (cg-RX-API-DMAC7.html)
WO (1) WO2018122606A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201904185B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY199385A (en) * 2016-12-28 2023-10-25 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs
WO2022197719A1 (en) 2021-03-15 2022-09-22 Tonix Pharmaceuticals Holding Corp. Tianeptine oxalate and naloxone combination for the treatment of major depressive disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2635461A1 (fr) * 1988-08-18 1990-02-23 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
WO2010051239A1 (en) * 2008-10-31 2010-05-06 Transform Pharmaceuticals, Inc. Tianeptine sulfate salt forms and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758528A (en) * 1970-03-13 1973-09-11 Science Union & Cie Tricyclic compounds
US5405842A (en) 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
FR2791891A1 (fr) 1999-04-07 2000-10-13 Adir Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
FR2810979B1 (fr) * 2000-06-29 2002-08-23 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
MY199385A (en) * 2016-12-28 2023-10-25 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2635461A1 (fr) * 1988-08-18 1990-02-23 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
WO2010051239A1 (en) * 2008-10-31 2010-05-06 Transform Pharmaceuticals, Inc. Tianeptine sulfate salt forms and methods of making and using the same

Also Published As

Publication number Publication date
AU2017385958A1 (en) 2019-07-11
MX2019007891A (es) 2019-12-16
US20180338984A1 (en) 2018-11-29
BR112019013244A2 (pt) 2019-12-24
EP3562812A1 (en) 2019-11-06
CA3048324A1 (en) 2018-07-05
US20200276208A1 (en) 2020-09-03
JP2023001340A (ja) 2023-01-04
NZ754797A (en) 2022-05-27
US10449203B2 (en) 2019-10-22
MY199385A (en) 2023-10-25
ZA201904185B (en) 2021-10-27
WO2018122606A1 (en) 2018-07-05
CN110418785A (zh) 2019-11-05
JP2020503330A (ja) 2020-01-30
IL267708A (en) 2019-08-29
US10946027B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
WO2017008773A1 (en) Crystalline forms of obeticholic acid
JP5899214B2 (ja) ４−［−２−［［５−メチル−１−（２−ナフタレニル）−１ｈ−ピラゾール−３−イル］オキシ］エチル］モルホリン塩酸塩の固体形態
US10946027B2 (en) Tianeptine oxalate salts and polymorphs
AU2021250851A1 (en) Crystalline salts and polymorphs of a P2X3 antagonist
KR20180014830A (ko) 결정성 화합물
RS61773B1 (sr) Kristalni oblici antagonista androgenog receptora, postupak njihove pripreme i upotrebe
US20240199544A1 (en) Crystalline forms of n,n-dimethyltryptamine and methods of using the same
Zhao et al. Preparation and solid-state characterization of dapsone pharmaceutical cocrystals through the supramolecular synthon strategy
WO2021242677A1 (en) Trka inhibitor
Hu et al. Solution growth and thermal treatment of crystals lead to two new forms of 2-((2, 6-dimethylphenyl) amino) benzoic acid
EP3917931A1 (en) Solid state forms of oclacitinib maleate
CN112174895B (zh) 一种雄性激素受体抑制剂的晶型及其制备方法
Costa et al. Enhancing Norfloxacin’s solubility: Development and characterization of new solid-state forms with p-aminobenzoic acid
HK40016628A (en) Tianeptine oxalate salts and polymorphs
CN101068827B (zh) 萨洒皂草配基的多晶型物
EP2986634B1 (en) Cocrystalline dhea formulations
CN114644669B (zh) 一种黄体酮共晶体的制备方法及其应用
WO2025237212A1 (zh) 一种嘧啶衍生物葡甲胺盐及其晶型
CA3247898A1 (en) CRYSTALLINE FORM OF A NEUROKIN-1 ANTAGONIST PRODIGITANT COMPOUND

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired